Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP cut its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 35.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,288 shares of the company’s stock after selling 24,485 shares during the quarter. Advantage Alpha Capital Partners LP owned about 0.10% of Omnicell worth $1,975,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in OMCL. Vanguard Group Inc. increased its stake in shares of Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after acquiring an additional 80,312 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after purchasing an additional 228,093 shares during the last quarter. Federated Hermes Inc. raised its stake in Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after purchasing an additional 909,480 shares during the period. Royce & Associates LP purchased a new position in Omnicell during the third quarter worth approximately $811,000. Finally, Liontrust Investment Partners LLP acquired a new position in shares of Omnicell in the 2nd quarter valued at $4,066,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $45.96 on Tuesday. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -117.85, a PEG ratio of 38.42 and a beta of 0.81. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74. The business has a 50-day moving average of $44.29 and a 200-day moving average of $37.57.

Analyst Ratings Changes

OMCL has been the subject of a number of research analyst reports. Barclays upped their price objective on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. raised their price objective on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Bank of America reiterated a “neutral” rating and set a $57.00 target price (up previously from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company lifted their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Omnicell presently has an average rating of “Hold” and an average price target of $52.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.